This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer | MicrobiomeTrials
← Back to trials NCT05896839
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer Recruiting PHASE1, PHASE2 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2024-07-24Est. Completion: 2027-01-31
Enrollment target: 16 participantsLocations UC San Diego Moores Cancer Center, La Jolla, California, United States Keck Medicine of USC Koreatown, Los Angeles, California, United States Los Angeles General Medical Center, Los Angeles, California, United States USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States Sibley Memorial Hospital, Washington D.C., District of Columbia, United States UM Sylvester Comprehensive Cancer Center at Aventura, Aventura, Florida, United States UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida, United States UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach, Florida, United States University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States UM Sylvester Comprehensive Cancer Center at Kendall, Miami, Florida, United States University of Miami Sylvester Comprehensive Cancer Center at Sole Mia, North Miami, Florida, United States UM Sylvester Comprehensive Cancer Center at Plantation, Plantation, Florida, United States Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States Other microbiome trials you might be interested in Acral Lentiginous Melanoma Clinical Stage III Cutaneous Melanoma AJCC v8 Clinical Stage IV Cutaneous Melanoma AJCC v8 Mucosal Melanoma
This phase II trial studies how pembrolizumab works before and after surgery in treating patients with stage III-IV high…
Birmingham, United States Est. completion Sep 1, 2022
Clinical Stage III Cutaneous Melanoma AJCC v8 Clinical Stage IV Cutaneous Melanoma AJCC v8 Metastatic Melanoma
Northwestern University, Chicago, Illinois, United States
Memorial Hospital East, Shiloh, Illinois, United States
University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters, Missouri, United States
Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri, United States
Washington University School of Medicine, St Louis, Missouri, United States
Siteman Cancer Center-South County, St Louis, Missouri, United States
Siteman Cancer Center at Christian Hospital, St Louis, Missouri, United States
NYU Langone Hospital - Long Island, Mineola, New York, United States
Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States Recurrent Melanoma
Unresectable Melanoma
This phase III trial studies how well initial treatment with ipilimumab and nivolumab followed by dabrafenib and trameti…
Birmingham, United States Est. completion Sep 30, 2023